Sign in Subscribe
Pharmaceutical industry

Biotech Mergers and Acquisitions Spark Activity in Quiet Industry

Strategic Insights

— 1 min read

A sudden wave of mergers and buyouts has sparked interest in the biotechnology industry, which is heavily reliant on deal-making to validate new ideas. Recent acquisitions, including Gilead Sciences' $2.5 billion purchase of Myogen Inc. and Millennium Pharmaceuticals' bid for AnorMed Inc., have highlighted the curious economics of biotechnology, where many companies aim to be acquired rather than grow profitable.

The biotech industry has seen a lackluster performance this year, with big biotech stocks experiencing an upswing over the past six weeks, giving them fuel to execute long-planned takeovers. Analysts suggest that the recent flurry of acquisitions could be a harbinger of more activity in the life-science business.

Key Takeaways:

  • The biotech industry relies heavily on deal-making to validate new ideas, with many companies aiming to be acquired rather than grow profitable.
  • 2004 was the last year in which a large number of biotech firms successfully went public, according to the National Venture Capital Association.
  • Recent acquisitions, including Gilead Sciences' $2.5 billion purchase of Myogen Inc. and Millennium Pharmaceuticals' bid for AnorMed Inc., have highlighted the complicated economics of biotechnology.
  • The benefits of acquisitions for investors include a lump sum of cash and the potential for a large company's cash flow and development expertise to help ensure a new drug reaches the market.
  • Industry analysts are split on whether the handful of big-ticket deals amount to a trend, with some predicting a phase of consolidation as firms bid to pick up smaller firms with drugs already in clinical trials.
  • A lively merger market is good for a biotech-dependent city like Cambridge, as it can lead to increased research spending and more companies wanting to get involved in the area due to the science being good.

Statistics:

  • The price of AnorMed's stock has more than doubled since Genzyme submitted a hostile bid on Aug. 30.
  • Myogen's shares leapt nearly 50 percent on Gilead's Monday pronouncement, single-handedly pushing the AmEx Biotechnology Index into positive territory for the day.
  • 2004 was a successful year for biotech firms going public, with a large number of companies successfully listing their shares.
  • The biotech industry has seen a lackluster performance this year, with big biotech stocks experiencing an upswing over the past six weeks.

Sources:

  • [Stephen Heuser, The Boston Globe, Oct. 5, 2006]
  • [National Venture Capital Association]
  • [IDG Ventures Boston]
  • [RA Capital Management LLC]
  • [Cowen & Co.]
  • [Columbia Management]
  • [Bank of America Corp.]

Read more